Latest News
Three novel radiopharmaceuticals have been evaluated for their potential to be utilized in PET imaging of tau proteins in humans. The results of the study have the potential to improve the way we diagnose and treat Alzheimer’s disease.
This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
Research demonstrates that female mice display a unique pattern of fluctuation in sex hormones during the ovarian cycle that could be linked to cognitive impairments such as Alzheimer’s disease.
Journal Articles
In this research article from Journal of Comparative Effectiveness Research, a new network meta-analysis compares lurasidone and brexpiprazole in acute schizophrenia.
In this research article from Pain Management, researchers investigate the effects of pregabalin, gabapentin and gastroretentive gabapentin on simulated driving performance.
This research article from Neurodegenerative Disease Management investigates how age and disease duration affects Parkinson’s treatment outcome with levodopa-carbidopa intestinal gel.
Autoimmune
Could hyaluronic acid contribute to chronic white matter injury?
Can living in a sunnier climate in your youth reduce the risk of MS?
Cerebrovascular disease
ANA 2018: key highlights and news stories
CNS/PNS/SNS
Advances in enteric neurobiology – the ‘brain’ in the gut in health and disease
SfN18: Advances in brain–computer interfaces may improve therapies and prosthetics
Cognitive/neurodegenerative disorders
Could novel radiopharmaceuticals for PET imaging improve the way we diagnose Alzheimer’s?
Ovarian cycle could modulate Alzheimer’s-related cognitive alterations in mice
Brains for Dementia Research: how human brain tissue could improve your research
Demyelinating disease
US FDA warns of stroke risk with multiple sclerosis drug: industry news round-up
Gilenya® gains EMA approval for pediatric multiple sclerosis
Warnings that stopping Gilenya® could make multiple sclerosis worse: industry news round-up
Development and pediatrics
US FDA warns of stroke risk with multiple sclerosis drug: industry news round-up
Gilenya® gains EMA approval for pediatric multiple sclerosis
Artificial intelligence and home videos: a new diagnostic method for autism?
Epilepsy and seizure
Cannabidiol for epilepsy expected to be available within 6 weeks: industry news round-up
First FDA-approved cannabinoid-derived drug for seizures
Epilepsy and cannabinoids: current consensus, controversies and future outlook
Genetics
SfN18: The potential of gene therapy in neurological disorders
Treasure trove of 102 genes associated with autism identified
Monogenic neurodevelopmental disorders may not be as simple as they seem
Headache
US FDA warns of stroke risk with multiple sclerosis drug: industry news round-up
Alzheimer’s drug development halted following toxic reaction: industry news round-up
Aimovig® receives EMA license for the prevention of migraine
Immune disorders and inflammation
Inflammatory disease and anxiety: could endocannabinoids be a mechanism of comorbidity?
FENS 2018: Immune system offers new way of treating Alzheimer’s disease
FENS 2018: Could anxiety and inflammation be treated with cannabis?
Infection
ANA 2018: key highlights and news stories
Further evidence links herpes virus to Alzheimer’s disease
Could Alzheimer’s disease be kick-started by periodontal bacteria?
Injury/trauma
Breakthrough spinal implant helps paralyzed men walk again
Is brain cooling after a traumatic brain injury beneficial for patients?
Movement disorders
BrainStorm scraps initial access to NurOwn® for amyotrophic lateral sclerosis
Neuro-ophthalmology
Vision in Alzheimer's disease: a focus on the anterior afferent pathway
Glaucoma research gives a glimpse of a novel neuroprotection mechanism
Neurometabolic
Epigenetics, opioids and immune regulation: interviews from SfN17
Jeffrey Iliff: glymphatics, Alzheimer’s and future directions
SfN17: Neurodegeneration and the microbiome – new research highlights
Neuromuscular
New genetic suspects identified for ALS and FTD
Novel discovery in motor neuron disease may pave the way for future treatments
EAN 2017: Guillain-Barré syndrome risk associated with month of birth
Neuropsychiatry
Warnings that stopping Gilenya® could make multiple sclerosis worse: industry news round-up
SfN18: The adolescent brain, mental health and substance abuse
Oncology/tumor
Warnings that stopping Gilenya® could make multiple sclerosis worse: industry news round-up
Could combination therapy be the future of neuroblastoma treatment?
Pain
Spinal cord stimulation enables paralyzed man to walk
Chronic pain relief: medical marijuana study identifies possible change in brain connections
NCTalks with Irene Tracey: lessons from pain, analgesia and anesthesia
Sleep
SfN18: Disrupted sleep may exacerbate anxiety and brain disorders
